Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site ...

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...

The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Miels outlined his roadmap to hit the company’s 2031 sales target.

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug, ...

iTeos Therapeutics announced that the GALAXIES Lung-201 Phase 2 trial, assessing the combination of belrestotug and dostarlimab for lung cancer, did not meet the criteria for clinically meaningful ...

GSK and CureVac forged their relationship during the Covid-19 pandemic, setting out to develop messenger RNA vaccines that could protect against the novel coronavirus and other infectious diseases.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks for a new generation of immunotherapy medicines. Interim analysis from two ...

GSK said it decided to halt the development of an experimental drug as a treatment for chronic cough after the medicine missed the key goal in a late-stage clinical study. The U.K. drugmaker said ...

LONDON, Feb 4 (Reuters) - GSK's new CEO Luke Miels said on Wednesday that the drugmaker will aim to lift sales growth and speed up work on new medicines in its next ‌phase of growth through a sharper ...